ZINFORO® (ceftaroline fosamil): Profiles of patients with CAP
Identifying a patient with CAP who may benefit from ZINFORO®
In patients with CAP, initial antimicrobial treatment modification occurs in >25% of patients and is frequently the result of insufficient response or treatment failure.1,*
George, a 70-year-old nursing home resident, presents with fever, cough and sputum production.
Marco presents with fever, cough and pleuritic chest pain and there has been no improvement with ceftriaxone.
Marie presents with fever, dyspnoea and cough.
Please note: The examples described here are not of actual patients, but fictitious representations of scenarios for which ZINFORO® (ceftaroline fosamil) could be considered.
Refer to the local product document for further information on ZINFORO®.2
*There is no experience with ZINFORO® (ceftaroline fosamil) in the treatment of CAP in the following patient groups: The immunocompromised, patients with severe sepsis/septic shock and severe underlying lung disease, patients with PORT risk Class V, and/or CAP requiring ventilation at presentation, CAP due to MRSA and patients requiring intensive care; the available clinical data cannot substantiate efficacy against PNSP.2
bpm, beats per minute; cSSTI, complicated skin and soft tissue infection; CAP, community-acquired pneumonia; ICU, intensive care unit; MRSA, methicillin-resistant Staphylococcus aureus; PNSP, penicillin-nonsusceptible pneumococci; PO2, partial pressure of oxygen; PORT, Pneumonia Patient Outcomes Research Team; RR, respiratory rate; URTI, upper respiratory tract infection.
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered Medical Practitioner*, please visit
https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 13th September 2019.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.